Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
$0.96
-0.1%		$1.31
$0.88
▼
$3.40
$25.50M0.5798,253 shs94,910 shs
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
$1.04
$1.11
$0.55
▼
$3.83
$98.90M1.77570,454 shs393,770 shs
ImmuCell Corporation stock logo
ICCC
ImmuCell
$10.90
-0.7%		$10.50
$4.52
▼
$12.10
$99.33M0.5419,907 shs44,696 shs
Rafael Holdings, Inc. stock logo
RFL
Rafael
$2.03
+2.5%		$2.35
$1.12
▼
$3.96
$102.96M0.3392,696 shs56,853 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
-0.07%-5.94%-28.40%-11.98%-67.70%
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
0.00%-7.96%+2.97%-8.77%-14.75%
ImmuCell Corporation stock logo
ICCC
ImmuCell
-0.73%-1.09%-7.00%+22.20%+66.92%
Rafael Holdings, Inc. stock logo
RFL
Rafael
+2.01%+2.27%-15.80%+56.88%+21.56%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
$0.96
-0.1%		$1.31
$0.88
▼
$3.40
$25.50M0.5798,253 shs94,910 shs
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
$1.04
$1.11
$0.55
▼
$3.83
$98.90M1.77570,454 shs393,770 shs
ImmuCell Corporation stock logo
ICCC
ImmuCell
$10.90
-0.7%		$10.50
$4.52
▼
$12.10
$99.33M0.5419,907 shs44,696 shs
Rafael Holdings, Inc. stock logo
RFL
Rafael
$2.03
+2.5%		$2.35
$1.12
▼
$3.96
$102.96M0.3392,696 shs56,853 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
-0.07%-5.94%-28.40%-11.98%-67.70%
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
0.00%-7.96%+2.97%-8.77%-14.75%
ImmuCell Corporation stock logo
ICCC
ImmuCell
-0.73%-1.09%-7.00%+22.20%+66.92%
Rafael Holdings, Inc. stock logo
RFL
Rafael
+2.01%+2.27%-15.80%+56.88%+21.56%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
1.00
SellN/AN/A
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
2.50
Moderate Buy$3.33220.51% Upside
ImmuCell Corporation stock logo
ICCC
ImmuCell
1.00
SellN/AN/A
Rafael Holdings, Inc. stock logo
RFL
Rafael
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest ABVC, RFL, ICCC, and CGTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/13/2026
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/2/2026
ImmuCell Corporation stock logo
ICCC
ImmuCell
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/24/2026
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/22/2026
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$3.00
6/15/2026
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
5/29/2026
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
5/28/2026
Rafael Holdings, Inc. stock logo
RFL
Rafael
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
5/15/2026
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
$510K49.95N/AN/A$0.52 per share1.85
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
N/AN/AN/AN/A$0.39 per shareN/A
ImmuCell Corporation stock logo
ICCC
ImmuCell
$29.93M3.29$0.19 per share56.95$2.99 per share3.65
Rafael Holdings, Inc. stock logo
RFL
Rafael
$920K114.74N/AN/A$1.91 per share1.06
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
-$7.91M-$0.40N/AN/AN/AN/A-46.56%-30.50%8/18/2026 (Estimated)
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
-$23.49M-$0.17N/AN/AN/AN/A-49.97%-39.34%N/A
ImmuCell Corporation stock logo
ICCC
ImmuCell
-$1.04M-$0.06N/AN/AN/A-1.82%-1.88%-1.22%N/A
Rafael Holdings, Inc. stock logo
RFL
Rafael
-$30.52M-$0.68N/AN/AN/A-3,321.74%-41.27%-35.32%10/28/2026 (Estimated)

Latest ABVC, RFL, ICCC, and CGTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
ImmuCell Corporation stock logo
ICCC
ImmuCell
$0.05$0.20+$0.15$0.20$5.40 million$7.19 million
8/12/2026Q2 2026
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
-$0.40-$0.03+$0.37-$0.03$0.11 millionN/A
8/6/2026Q2 2026
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
-$0.0633-$0.04+$0.0233-$0.04$5.00 millionN/A
5/18/2026Q1 2026
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
N/A-$0.06N/A-$0.06N/AN/A
5/14/2026Q1 2026
ImmuCell Corporation stock logo
ICCC
ImmuCell
$0.05$0.21+$0.16$0.21$5.40 million$10.36 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
N/AN/AN/AN/AN/A
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
N/AN/AN/AN/AN/A
ImmuCell Corporation stock logo
ICCC
ImmuCell
N/AN/AN/AN/AN/A
Rafael Holdings, Inc. stock logo
RFL
Rafael
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
N/A
0.12
0.12
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
N/A
5.92
5.92
ImmuCell Corporation stock logo
ICCC
ImmuCell
0.24
4.82
2.60
Rafael Holdings, Inc. stock logo
RFL
Rafael
N/A
3.16
3.14

Institutional Ownership

CompanyInstitutional Ownership
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
11.38%
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
43.35%
ImmuCell Corporation stock logo
ICCC
ImmuCell
13.47%
Rafael Holdings, Inc. stock logo
RFL
Rafael
11.30%

Insider Ownership

CompanyInsider Ownership
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
19.00%
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
11.11%
ImmuCell Corporation stock logo
ICCC
ImmuCell
5.70%
Rafael Holdings, Inc. stock logo
RFL
Rafael
32.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
3026.55 million21.51 millionNot Optionable
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
2095.09 million84.53 millionNot Optionable
ImmuCell Corporation stock logo
ICCC
ImmuCell
709.05 million8.53 millionNot Optionable
Rafael Holdings, Inc. stock logo
RFL
Rafael
2052.00 million34.89 millionOptionable

Recent News About These Companies

Short Interest in Rafael Holdings, Inc. (NYSE:RFL) Rises By 89.0%
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/short-interest-in-rafael-holdings-inc-nyserfl-rises-by-890-2026-07-30/
Rafael Holdings, Inc. (NYSE:RFL) Sees Large Growth in Short Interest
July 16, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/rafael-holdings-inc-nyserfl-sees-large-growth-in-short-interest-2026-07-16/
Rafael Holdings Inc Share Price (RFL.US)
July 15, 2026  |  lse.co.ukhttps://www.lse.co.uk/SharePrice.html?shareprice=RFL.US
Rafael Holdings Insider Trading Activity | NYSE:RFL | Benzinga
July 2, 2026  |  benzinga.comhttps://www.benzinga.com/quote/RFL/insider-trades
Rafael Holdings: The Second Half Of Calendar 2026 Could Define This Company Forever
June 29, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4918451-rafael-holdings-second-half-of-calendar-2026-could-define-this-company
Rafael Holdings (NYSE:RFL) Stock, Short Interest Report
June 25, 2026  |  benzinga.comhttps://www.benzinga.com/quote/RFL/short-interest
Rafael Holdings (NYSE: RFL) - Share Price and Research
June 25, 2026  |  intelligentinvestor.com.auI
Rafael B Stock Price History
June 11, 2026  |  investing.comhttps://www.investing.com/equities/rafael-b-historical-data
Rafael Holdings, Inc. Reports Q3 Fiscal 2026 Financial Results and Progress on Phase 3 TransportNPC™ Trial
June 11, 2026  |  quiverquant.comQ
Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results
June 11, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/11/3310357/0/en/rafael-holdings-reports-third-quarter-fiscal-2026-financial-results.html
Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick ...
June 10, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/rafael-holdings-announces-completion-last-113000912.html
Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
June 10, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/10/3309598/0/en/rafael-holdings-announces-completion-of-last-patient-last-visit-for-pivotal-phase-3-transportnpc-study-evaluating-trappsol-cyclo-for-the-treatment-of-niemann-pick-disease-type-c.html
Rafael Holdings Insider Ups Holding By 1,810% During Year
April 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/rafael-holdings-insider-ups-holding-142622929.html
Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve ...
April 22, 2026  |  caledonianrecord.comC
Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer’s Disease”
April 22, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/rafael-holdings-announces-patent-licensing-agreement-with-mit-for-small-molecules-to-improve-myelination-in-apoe4-positive-alzheimer-s-disease-1036048049
Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer's Disease”
April 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/22/3278798/0/en/rafael-holdings-announces-patent-licensing-agreement-with-mit-for-small-molecules-to-improve-myelination-in-apoe4-positive-alzheimer-s-disease.html
Rafael Holdings Inc. Wt
April 4, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/rfl.wt/company-people
Rafael Holdings, Inc.: Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results
March 17, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-03/67960421-rafael-holdings-inc-rafael-holdings-reports-second-quarter-fiscal-2026-financial-results-399.htm
Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results
March 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/16/3256686/0/en/rafael-holdings-reports-second-quarter-fiscal-2026-financial-results.html
Rafael Holdings (NYSE:RFL) Short Interest Falls on NYSE Composite
March 1, 2026  |  kalkinemedia.comK
Rafael Deepens Space Focus As IPO Decision Looms
February 4, 2026  |  aviationweek.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVC BioPharma stock logo

ABVC BioPharma NASDAQ:ABVC

$0.96 0.00 (-0.07%)
Closing price 08/13/2026 04:00 PM Eastern
Extended Trading
$0.99 +0.03 (+3.61%)
As of 04:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

Cognition Therapeutics stock logo

Cognition Therapeutics NASDAQ:CGTX

$1.04 0.00 (0.00%)
Closing price 08/13/2026 04:00 PM Eastern
Extended Trading
$1.04 +0.00 (+0.48%)
As of 08:27 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

ImmuCell stock logo

ImmuCell NASDAQ:ICCC

$10.90 -0.08 (-0.73%)
Closing price 08/13/2026 04:00 PM Eastern
Extended Trading
$10.80 -0.10 (-0.94%)
As of 08:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Rafael stock logo

Rafael NYSE:RFL

$2.03 +0.05 (+2.53%)
Closing price 08/13/2026 03:59 PM Eastern
Extended Trading
$1.74 -0.29 (-14.24%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas